Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

RANITIDINE FOR IMPURITY A IDENTIFICATION CRS (15 MG)

RANITIDINE FOR IMPURITY A IDENTIFICATION CRS (15 MG)

66357-59-3

DISCOVER
BILBERRY DRY EXTRACT HRS (400MG)

BILBERRY DRY EXTRACT HRS (400MG)

NA

DISCOVER
THIOCOLCHICOSIDE HYDRATE CRS (60 MG)

THIOCOLCHICOSIDE HYDRATE CRS (60 MG)

602-41-5

DISCOVER
THIOCOLCHICOSIDE CRYSTALLISEDFROM ETHANOL CRS (10 MG)

THIOCOLCHICOSIDE CRYSTALLISEDFROM ETHANOL CRS (10 MG)

602-41-5

DISCOVER
THIOCOLCHICOSIDE FOR SYSTEM SUITABILITY CRS (10 MG)

THIOCOLCHICOSIDE FOR SYSTEM SUITABILITY CRS (10 MG)

602-41-5

DISCOVER
Nalidixic acid impurity C CRS, 20mg

Nalidixic acid impurity C CRS, 20mg

87-13-8

DISCOVER
AMOROLFINE HYDROCHLORIDE CRS (10 MG)

AMOROLFINE HYDROCHLORIDE CRS (10 MG)

78613-38-4

DISCOVER
AMOROLFINE FOR SYSTEM SUITABILITY CRS (10 MG)

AMOROLFINE FOR SYSTEM SUITABILITY CRS (10 MG)

78613-38-4

DISCOVER
ESCITALOPRAM OXALATE CRS (10 MG)

ESCITALOPRAM OXALATE CRS (10 MG)

219861-08-2

DISCOVER
ESCITALOPRAM FOR SYSTEM SUITABILITY CRS (15 MG)

ESCITALOPRAM FOR SYSTEM SUITABILITY CRS (15 MG)

219861-08-2

DISCOVER
LOW-SUBSTITUTED HYDROXYPROPYLCELLULOSE CRS (50 MG)

LOW-SUBSTITUTED HYDROXYPROPYLCELLULOSE CRS (50 MG)

9004-64-2

DISCOVER
METHYLPREDNISOLONE FOR SYSTEMSUITABILITY A CRS (10 MG)

METHYLPREDNISOLONE FOR SYSTEMSUITABILITY A CRS (10 MG)

83-43-2

DISCOVER